Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

– Exclusive worldwide license agreement for preclinical ROR1 ADC, on track to submit IND in 1Q 2025

– Proprietary ADC platform enhances Immunome’s development of next-generation ADC programs

– Zentalis to receive up-front payment of $35 million in cash and Immunome common stock and is eligible to receive up to $275 million of milestone payments and mid-to-high single-digit royalties

See more here